| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.069 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.28 | 0.04 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.091 | 0.04 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.04 |